Rifapentine
- Generic Name
- Rifapentine
- Brand Names
- Priftin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H64N4O12
- CAS Number
- 61379-65-5
- Unique Ingredient Identifier
- XJM390A33U
- Background
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
- Indication
For the treatment of pulmonary tuberculosis.
- Associated Conditions
- Active Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- -
The Correlate of Risk Targeted Intervention Study
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- University of Cape Town
- Target Recruit Count
- 2927
- Registration Number
- NCT02735590
- Locations
- 🇿🇦
Stellenbosch Immunology Research Group, Cape Town, Western Cape, South Africa
🇿🇦Centre for the Aids Programme of Research in South Africa (CAPRISA), Durban, KwaZulu-Natal, South Africa
🇿🇦South African Tuberculosis Vaccine Initiative (SATVI), Worcester, Western Cape, South Africa
Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 60
- Registration Number
- NCT02563327
- Locations
- 🇺🇬
Mulago Hospital, Kampala, Uganda
TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens
- Conditions
- Interventions
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 2516
- Registration Number
- NCT02410772
- Locations
- 🇨🇳
TBTC Site 36 TB and Chest Service of Hong Kong, China, Hong Kong, China
🇰🇪TBTC Site 02/ ACTG 12501 Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS, Kericho, Kericho County, Kenya
🇿🇦TBTC Site 01/ACTG Site 8950 FAM CRU, Parow Valley, Western Cape, South Africa
PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 32
- Registration Number
- NCT02216331
- Locations
- 🇺🇸
Celerion (MDS Pharma Services), Lincoln, Nebraska, United States
High Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2010-01-07
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 60
- Registration Number
- NCT01043575
- Locations
- 🇺🇬
Uganda / Case Western Reserve Research Collaboration, Kampala, Uganda
🇺🇸Audie L. Murphy VA Medical Center, San Antonio, Texas, United States
🇺🇸Denver Public Health, Denver, Colorado, United States
TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 865
- Registration Number
- NCT00694629
- Locations
- 🇺🇸
Washington DC Veterans Administration Medical Center, Washington DC, District of Columbia, United States
🇪🇸Agencia de Salut Publica, Barcelona, Spain
🇺🇸University of North Texas Health Science Center, Fort Worth, Texas, United States
Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine
- Conditions
- Interventions
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 15
- Registration Number
- NCT00460759
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Tuberculosis Prevention for HIV Infected Adults
- Conditions
- Interventions
- First Posted Date
- 2003-03-28
- Last Posted Date
- 2012-10-22
- Target Recruit Count
- 1148
- Registration Number
- NCT00057122
- Locations
- 🇿🇦
Chris Hani Baragwanath Hospital, Soweto, South Africa
TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis
- Conditions
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2005-09-13
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 150
- Registration Number
- NCT00023426
- Locations
- 🇺🇸
Thomas Street Clinic, Houston, Texas, United States
🇺🇸New York University School of Medicine, New York, New York, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine
- Conditions
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2005-09-13
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 36
- Registration Number
- NCT00023387
- Locations
- 🇺🇸
LA County/USC Medical Center, Los Angeles, California, United States
🇺🇸Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.